Pila Pharma (PILA) Q2 2025 earnings summary

Executive summary

• Strategic focus shifted to obesity drug development alongside type 2 diabetes, driven by industry feedback and market opportunity, with strong engagement from pharmaceutical partners interested in differentiated TRPV1 antagonist approaches.

• The company completed an oversubscribed rights issue, raising nearly SEK 30 million before costs, providing a solid financial base for upcoming studies.

• Management and board members increased their holdings, with significant set-offs for executive remuneration, now holding about 15% of shares.

• Positive industry response to the TRPV1 antagonist project, with plans to demonstrate Proof of Concept in preclinical and clinical obesity studies.

• The company is preparing to announce a top-tier preclinical partner for upcoming studies.

Financial highlights

• Operating income for H1 2025 was TSEK 851, up from TSEK 683 year-over-year.

• EBIT for H1 2025 was TSEK -4,092, nearly unchanged from TSEK -4,082 in H1 2024.

• Net result for H1 2025 was TSEK -4,102, compared to TSEK -4,086 in H1 2024.

• Cash at period end was TSEK 1,082, down from TSEK 2,543 at June 2024, with significant improvement post-period due to the rights issue.

• Burn rate remained consistent with the previous half-year period.

Outlook and guidance

• Preclinical in vivo rat studies for obesity are set to begin in autumn, with results expected before the TO2 warrant exercise period in February 2026.

• Pending positive preclinical results and continued funding, clinical trials in humans with obesity are planned.

• Funds raised are sufficient to finance rat obesity studies and clinical trial application preparations for both diabetes and obesity.

• No official runway guidance, but current funding is sufficient for planned preclinical activities.

• Additional funding possible from warrant exercise, potentially up to SEK 90 million.